NRF2-Mediated Proteostatic Convergence: Shared Oxidative Stress Response Failure Links PD (SNCA Aggregation) and AD (Abeta/Tau Accumulation)

Target: NFE2L2,KEAP1,HMOX1,SQSTM1,PSMB5 Composite Score: 0.700 Price: $0.50▲47.4% Citation Quality: Pending neurodegeneration Status: proposed
☰ Compare⚔ Duel⚛ Collideinteract with this hypothesis
📄 Export → LaTeX
Select venue
arXiv Preprint NeurIPS Nature Methods PLOS ONE
🌐 Open in Overleaf →
📖 Export BibTeX
⚠ Orphaned Senate Quality Gates →
Evidence Strength Pending (0%)
5
Citations
1
Debates
5
Supporting
2
Opposing
Quality Report Card click to collapse
B+
Composite: 0.700
Top 17% of 1875 hypotheses
T4 Speculative
Novel AI-generated, no external validation
Needs 1+ supporting citation to reach Provisional
B+ Mech. Plausibility 15% 0.75 Top 23%
B+ Evidence Strength 15% 0.75 Top 9%
B Novelty 12% 0.65 Top 55%
A Feasibility 12% 0.80 Top 24%
A Impact 12% 0.80 Top 34%
F Druggability 10% 0.00 Top 50%
F Safety Profile 8% 0.00 Top 50%
F Competition 6% 0.00 Top 50%
F Data Availability 5% 0.00 Top 50%
C+ Reproducibility 5% 0.50 Top 63%
Evidence
5 supporting | 2 opposing
Citation quality: 45%
Debates
0 sessions
No debates yet
Convergence
0.00 F 30 related hypothesis share this target

Description

Convergence hypothesis: NRF2 (NFE2L2) is the central transcriptional regulator whose failure explains parallel proteostatic collapse in both PD and AD, making it a high-priority cross-disease target.

PD-specific mechanism: NRF2 regulates ARE-containing genes (HMOX1, NQO1, GCLC, GSTM1) that detoxify reactive oxygen species generated by mitochondrial dysfunction and neuromelanin iron accumulation. In PD, KEAP1 releases NRF2 in early disease to compensate, but chronic oxidative stress (elevated 4-HNE, 8-OHdG in substantia nigra) eventually overwhelms this response, leading to NRF2 nuclear translocation failure. The resulting proteasome (PSMB5, PSMD4) and autophagy (LAMP2A, GABARAP) failure accelerates α-synuclein aggregation.

...

No AI visual card yet

Curated Mechanism Pathway

Curated pathway diagram from expert analysis

flowchart TD
    A["Oxidative Stress
PD SNCA and AD Abeta Tau Burden"] B["KEAP1 NRF2 Switch
NFE2L2 Stabilization"] C["ARE Gene Program
HMOX1 NQO1 GCLC GSTM1"] D["SQSTM1 Autophagy Coupling
Proteostatic Clearance"] E["Chronic Stress NRF2 Failure
Antioxidant Exhaustion"] F["Proteasome and Autophagy Collapse
Aggregate Accumulation"] G["PD AD Shared Vulnerability
Proteostatic Convergence"] A --> B B --> C C --> D A --> E E --> F D -.->|"when insufficient"| F F --> G style B fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7 style G fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.
Mechanistic 0.75 (15%) Evidence 0.75 (15%) Novelty 0.65 (12%) Feasibility 0.80 (12%) Impact 0.80 (12%) Druggability 0.00 (10%) Safety 0.00 (8%) Competition 0.00 (6%) Data Avail. 0.00 (5%) Reproducible 0.50 (5%) KG Connect 0.50 (8%) 0.700 composite
7 citations 7 with PMID 5 medium Validation: 45% 5 supporting / 2 opposing
For (5)
5
No opposing evidence
(2) Against
High Medium Low
High Medium Low
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
4
3
MECH 4CLIN 3GENE 0EPID 0
ClaimStanceCategorySourceStrength ↕Year ↕Quality ↕PMIDsAbstract
Berberine ameliorates iron levels and ferroptosis …SupportingMECHPhytomedicine MEDIUM2023-PMID:37506403-
Oxidative stress in Alzheimer's disease: curr…SupportingCLINMol Biol Rep MEDIUM2024-PMID:38165499-
Therapeutic effect of nicotinamide mononucleotide …SupportingCLINBiomed Pharmaco… MEDIUM2024-PMID:39053426-
Advances in KEAP1-based PROTACs as emerging therap…SupportingCLINRedox Biol MEDIUM2025-PMID:40714402-
Should evidence of an autolysosomal de-acidificati…SupportingMECHAutophagy MEDIUM2023-PMID:37482676-
No claimOpposingMECH- MODERATE2022-PMID:35456966-
No claimOpposingMECH- MODERATE2022-PMID:35342364-
Legacy Card View — expandable citation cards

Supporting Evidence 5

Berberine ameliorates iron levels and ferroptosis in the brain of 3 × Tg-AD mice. MEDIUM
Phytomedicine · 2023 · PMID:37506403
Oxidative stress in Alzheimer's disease: current knowledge of signaling pathways and therapeutics. MEDIUM
Mol Biol Rep · 2024 · PMID:38165499
Therapeutic effect of nicotinamide mononucleotide on Alzheimer's disease through activating autophagy and anti… MEDIUM
Therapeutic effect of nicotinamide mononucleotide on Alzheimer's disease through activating autophagy and anti-oxidative stress.
Biomed Pharmacother · 2024 · PMID:39053426
Advances in KEAP1-based PROTACs as emerging therapeutic modalities: Structural basis and progress. MEDIUM
Redox Biol · 2025 · PMID:40714402
Should evidence of an autolysosomal de-acidification defect in Alzheimer and Parkinson diseases call for cauti… MEDIUM
Should evidence of an autolysosomal de-acidification defect in Alzheimer and Parkinson diseases call for caution in prescribing chronic PPI and DMARD?
Autophagy · 2023 · PMID:37482676

Opposing Evidence 2

No claim MODERATE
No claim MODERATE
Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.

No linked debates yet. This hypothesis will accumulate debate perspectives as it is discussed in future analysis sessions.

Price History

0.600.670.75 0.82 0.52 2026-04-212026-04-242026-04-27 Market PriceScoreevidencedebate 7 events
7d Trend
Rising
7d Momentum
▲ 36.6%
Volatility
Low
0.0071
Events (7d)
6

Clinical Trials (1) Relevance: 80%

0
Active
0
Completed
0
Total Enrolled
PHASE2
Highest Phase
Broccoli Sprout Extracts Trial to See if NRF2 is Enhanced by Sulforaphane Treatment in Patients With COPD PHASE2
COMPLETED · NCT01335971 · Johns Hopkins University
COPD
Sulforaphane 25 Sulforaphane 150 Placebo

📚 Cited Papers (7)

No extracted figures yet
Biomarker of Neuroinflammation in Parkinson's Disease.
Int J Mol Sci (2022) · PMID:35456966
No extracted figures yet
No extracted figures yet
No extracted figures yet
No extracted figures yet
No extracted figures yet
No extracted figures yet

📅 Citation Freshness Audit

Freshness score = exp(-age×ln2/5): halves every 5 years. Green >0.6, Amber 0.3–0.6, Red <0.3.

No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.

📙 Related Wiki Pages (0)

No wiki pages linked to this hypothesis yet.

࢐ Browse all wiki pages

📓 Linked Notebooks (0)

No notebooks linked to this analysis yet. Notebooks are generated when Forge tools run analyses.

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas
→ Browse all arenas & tournaments

📊 Resource Economics & ROI

Moderate Efficiency Resource Efficiency Score
0.50
32.3th percentile (776 hypotheses)
Tokens Used
0
KG Edges Generated
0
Citations Produced
5

Cost Ratios

Cost per KG Edge
0.00 tokens
Lower is better (baseline: 2000)
Cost per Citation
0.00 tokens
Lower is better (baseline: 1000)
Cost per Score Point
0.00 tokens
Tokens / composite_score

Score Impact

Efficiency Boost to Composite
+0.050
10% weight of efficiency score
Adjusted Composite
0.750

How Economics Pricing Works

Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.

High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.

Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.

Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.

📋 Reviews View all →

Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.

💬 Discussion

No DepMap CRISPR Chronos data found for NFE2L2,KEAP1,HMOX1,SQSTM1,PSMB5.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for NFE2L2,KEAP1,HMOX1,SQSTM1,PSMB5 →
Loading history…

⚖️ Governance History

No governance decisions recorded for this hypothesis.

Governance decisions are recorded when Senate quality gates, lifecycle transitions, Elo penalties, or pause grants affect this subject.

Browse all governance decisions →

Related Hypotheses

Gut Microbiome Remodeling to Prevent Systemic NLRP3 Priming in Neurodegeneration
Score: 0.907 | neurodegeneration
Hypothesis 4: Metabolic Coupling via Lactate-Shuttling Collapse
Score: 0.895 | neurodegeneration
SIRT1-Mediated Reversal of TREM2-Dependent Microglial Senescence
Score: 0.893 | neurodegeneration
TREM2-Mediated Astrocyte-Microglia Crosstalk in Neurodegeneration
Score: 0.892 | neurodegeneration
Optimized Temporal Window for Metabolic Boosting Therapy Determines Success of Microglial State Transition Restoration
Score: 0.887 | neurodegeneration

Estimated Development

Estimated Cost
$0
Timeline
0 months

🧪 Falsifiable Predictions (2)

2 total 0 confirmed 0 falsified
NRF2 activator (dimethyl fumarate 30mg/kg/day PO 8 weeks) will reduce both soluble α-synuclein (Ser129-P) and total tau (Tau5) in A53T SNCA transgenic mice.
open conf: 0.50
Falsified by: A53T SNCA transgenic mice treated with dimethyl fumarate 30mg/kg/day PO for 8 weeks show >40% reduction in pSer129 α-synuclein and total tau (Tau5) in ventral midbrain by ELISA vs. vehicle-treated controls.
KEAP1/NRF2/CUL3 ratio in post-mortem PD putamen and AD hippocampus shows KEAP1 elevated >2-fold and NRF2 reduced >50% compared to age-matched controls.
open conf: 0.50
Falsified by: Quantitative proteomics (TMT labeling) of PD putamen (n>=10) and AD hippocampus (n>=10) shows KEAP1 >2-fold elevated and NRF2 >50% reduced vs. age-matched controls (n>=10 each).

Knowledge Subgraph (0 edges)

No knowledge graph edges recorded

3D Protein Structure

🧬 NFE2L2 — Search for structure Click to search RCSB PDB
🔍 Searching RCSB PDB for NFE2L2 structures...
Querying Protein Data Bank API

Community Feedback

0 0 upvotes · 0 downvotes
💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)

Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.